Glucagon-like peptide-1, glucose homeostasis and diabetes

This publication has 53 references indexed in Scilit:

• Response to Comment on: Knop et al. (2007) Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes 56:1951–1959
  Diabetes, 2008
• Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat
  Biochemical and Biophysical Research Communications, 2007
• Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
  Diabetologia, 2007
• Efficacy and Safety of Incretin Therapy in Type 2 Diabetes
  JAMA, 2007
• Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
  Diabetes Care, 2007
• Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
  Critical Reviews in Clinical Laboratory Sciences, 2003
• Incretin hormones – an update
  Scandinavian Journal of Clinical and Laboratory Investigation, 2001
• GIF biology and fat metabolism
  Life Sciences, 1999
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
  The Journal of Clinical Endocrinology & Metabolism, 1995
• Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
  European Journal of Biochemistry, 1993